NeuroPace ( (NPCE) ) has provided an update.
On April 2, 2025, NeuroPace, Inc. announced a strategic shift in its product portfolio, focusing on its core RNS System and ending its distribution agreement with DIXI Medical USA Corp. for SEEG products by September 30, 2025. This move is part of a broader plan to concentrate resources on expanding opportunities for the RNS System, including new indications and AI-enabled software, while maintaining 2025 revenue guidance and aiming for cash flow breakeven by 2027.
More about NeuroPace
NeuroPace, Inc., based in Mountain View, California, is a medical device company dedicated to improving the lives of individuals with epilepsy by reducing or eliminating seizures. The company offers the RNS System, a unique brain-responsive platform that provides personalized, real-time treatment at the source of seizures, aiming to enhance the standard of care for patients with drug-resistant epilepsy.
YTD Price Performance: 13.21%
Average Trading Volume: 240,030
Technical Sentiment Signal: Strong Sell
Current Market Cap: $400.2M
For an in-depth examination of NPCE stock, go to TipRanks’ Stock Analysis page.